Compare FRPT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRPT | SUPN |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 2014 | 2012 |
| Metric | FRPT | SUPN |
|---|---|---|
| Price | $64.17 | $50.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $76.33 | $61.60 |
| AVG Volume (30 Days) | ★ 923.5K | 628.9K |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 169.38 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $1,079,494,000.00 | $681,539,000.00 |
| Revenue This Year | $15.47 | $8.32 |
| Revenue Next Year | $9.50 | $23.64 |
| P/E Ratio | $26.55 | ★ N/A |
| Revenue Growth | ★ 16.34 | 4.54 |
| 52 Week Low | $46.76 | $29.16 |
| 52 Week High | $164.07 | $57.65 |
| Indicator | FRPT | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 51.47 |
| Support Level | $60.98 | $49.41 |
| Resistance Level | $64.49 | $52.34 |
| Average True Range (ATR) | 2.32 | 1.54 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 79.15 | 48.19 |
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.